Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Description: The AFL4 monoclonal antibody reacts with the mouse VEGF receptor-3, also known as Flt-4. This 195 kDa molecule was identified as an endothelial-specific member of the receptor tyrosine kinase (RTK) family. During early embryogenesis all endothelial cells express VEGFR-3, while in the adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. However, VEGFR-3 expression is induced in the adult tissue upon tumor implementation suggesting an important role for this receptor in the tumor angiogenesis. VEGF-C and VEGF-D bind to and activate VEGFR-3. AFL4 is an antagonist mAb.
Applications Reported: The AFL4 antibody has been reported for use in flow cytometric analysis.
Applications Tested: The AFL4 antibody has been tested by flow cytometric analysis of in vitro differentiated mouse endothelial cells. In brief, mouse ES cells were incubated on collagen IV matrix for 4 days and subsequently stimulated with VEGF under serum free conditions to induce further differentiation. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Storage and handling: Use in a sterile environment.
Filtration: 0.2 µm post-manufacturing filtered.
Purity: Greater than 90%, as determined by SDS-PAGE.
Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.
Aggregation: Less than 10%, as determined by HPLC.
Vascular endothelial growth factor is a key regulator of blood vessel development in embryos and angiogenesis in adult tissues. Unlike VEGF, the related VEGFC stimulates the growth of lymphatic vessels through its specificl ymphatic endothelial receptor VEGFR-3. In 1998, Dumont showed that targeted inactivation of the VEGFR-3 gene in mice resulted in defective blood vessel development in early embryos. Vasculogenesis and angiogenesis occurred, but large vessels became abnormally organized with defective lumens, leading to fluid accumulation in the pericardial cavity and cardiovascular failure at embryonic day 9.5. Thus, VEGFR3 has an essential role in the development of theembryonic cardiovascular system before the emergence of the lymphatic vessels.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: chylous ascites; FLT-4; Fms-like tyrosine kinase 4; receptor protein tyrosine kinase; soluble VEGFR 3; sVEGFR 3; Tyrosine-protein kinase receptor FLT4; Vascular endothelial growth factor receptor 3; vascular endothelial growth factor receptor-3; VEGF R3; VEGFR-3
Gene Aliases: AI323512; Chy; Flt-4; Flt4; VEGFR-3; VEGFR3
UniProt ID: (Mouse) P35917
Entrez Gene ID: (Mouse) 14257
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support
